Concomitant use of oral tyrosine kinase inhibitors (TKIs) with bisphosphonates appear to be associated with improved outcomes in patients with renal cell carcinoma (RCC) and bone involvement, according to new study.
The study included 76 RCC patients: 27 receiving TKIs alone and 49 receiving both TKIs concomitantly with bisphosphonates. The bisphosphonate group had a significantly better partial response rate than the TKI-alone group (38% vs. 16%) as well as significantly better median progression-free survival (7.0 vs. 4.0 months), and median overall survival (17 vs. 7.0 months), the researchers reported in the British Journal of Cancer (2012;107;1665-1671). The combination arm, however, had a 10% incidence of osteonecrosis of the jaw (ONJ), an adverse effect of bisphosphonates.
“Careful dental protective measures, limitation of the duration of bisphosphonate use and immediate interruption in case of the first signs of ONJ are indicated,” the authors concluded.